121 completed, 57 recruiting, 45 terminated, 44 unknown. 356 Phase 2, 100 Phase 1, 9 Phase 3.
Follow nab-paclitaxel: new trials by email Literature Review of nab-paclitaxel trials Research Report on nab-paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma. GnP, FOLFIRINOX - Pancreatic Adenocarcinoma Resectable, Non Metastatic | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 42 | 2027-01-01 | 2026-09-15 |
| Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Exelixis | 60 | 2026-12-15 | 2026-09-29 |
| Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer Gemcitabine (1000 mg/m2), Nab-paclitaxel, L-glutamine - Pancreatic Cancer | Phase 2 | Not yet recruiting | Jun Gong, MD | 200 | 2026-12-01 | 2026-10-08 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma Rimegepant, Tislelizumab, Nab-paclitaxel - Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 220 | 2026-10-01 | 2026-09-10 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer Relacorilant, Nab-paclitaxel - Recurrent or Metastatic Cervical Cancer | Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 63 | 2026-10-01 | 2026-08-13 |
| GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC SHR-1701, Apatinib, gemcitabine - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 45 | 2026-09-10 | 2026-09-03 |
| Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma Finotonlimab, Nab-paclitaxel, carboplatin - Head & Neck Cancer | Phase 2 | Not yet recruiting | Tang-Du Hospital | 15 | 2026-08-23 | 2026-08-07 |
| A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel - Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | AbbVie | 168 | 2026-08-17 | 2026-10-13 |
| GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) GB268, Nab-Paclitaxel, Datopotamab Deruxtecan (Dato-DXd) - Breast Cancer (Locally Advanced or Metastatic) | Phase 1 / Phase 2 | Not yet recruiting | Eddingpharm (Zhuhai) Co., Ltd. | 270 | 2026-08-01 | 2026-07-31 |
| A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC - Solid Tumors | Phase 2 | Recruiting | Bristol-Myers Squibb | 260 | 2026-07-27 | 2026-10-06 |
| Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel - HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 70 | 2026-07-22 | 2026-06-04 |
| Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 140 | 2026-07-01 | 2026-07-17 |
| Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma Intermittent Hypoxic Training (IHT), Standard Neoadjuvant Chemo-immunotherapy - Lung Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC) | Phase 2 | Not yet recruiting | zhang yi | 60 | 2026-06-01 | 2026-06-01 |
| SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer SYHX2011, Carboplatin, Enlonstobart - Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Chest Hospital | 396 | 2026-06-01 | 2026-06-29 |
| SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer SCTB41, Tislelizumab, Paclitaxel - Double Blind | Phase 2 / Phase 3 | Recruiting | Sinocelltech Ltd. | 410 | 2026-05-09 | 2026-06-23 |
Showing 20 of 356. Sign in to see all of them.
Pancreatic Neoplasms (94) · Breast Neoplasms (54) · Carcinoma, Non-Small-Cell Lung (43) · Triple Negative Breast Neoplasms (31) · Neoplasm Metastasis (15) · Lung Neoplasms (14) · Neoplasms (14) · Squamous Cell Carcinoma of Head and Neck (12) · Head and Neck Neoplasms (11) · Melanoma (9) · Colorectal Neoplasms (8) · Adenocarcinoma (6) · Cholangiocarcinoma (6) · Sarcoma (6) · Stomach Neoplasms (6)
ImmunityBio, Inc. (20) · M.D. Anderson Cancer Center (11) · Bristol-Myers Squibb (9) · Fudan University (8) · Celgene (7) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5) · Chinese PLA General Hospital (5) · Emory University (5) · National Cancer Institute (NCI) (5) · Tianjin Medical University Cancer Institute and Hospital (5) · University of Washington (5) · Washington University School of Medicine (5) · Hoffmann-La Roche (4) · Pancreatic Cancer Research Team (4) · Shanghai Pulmonary Hospital, Shanghai, China (4)
United States (188) · China (99) · Spain (35) · Italy (27) · Germany (26) · Australia (22) · France (22) · United Kingdom (20) · Canada (19) · South Korea (18) · Taiwan (15) · Belgium (14) · Japan (13) · Switzerland (11) · Brazil (9)
Jared Weiss, MD (4) · Douglas R Adkins, M.D. (2) · Dung Le, MD (2) · Erwei Song, M.D., Ph.D. (2) · Everett Vokes, MD (2) · Hailong Hu, PhD (2) · Ileana Elias, M.D. (2) · Mitsuhiko Iwamoto, MD, PhD (2) · Peng Zhang, PhD (2)
PMID 31401903, PMID 24703985, PMID 25579459, PMID 25845992, PMID 27244882, PMID 27404453, PMID 27701653, PMID 28114604, PMID 28701571, PMID 28869790, PMID 29119276, PMID 29158367, PMID 29190925, PMID 29228091, PMID 29232172, PMID 29273007, PMID 29346519, PMID 29879283, PMID 30115734, PMID 30149366, PMID 30220407, PMID 30481287, PMID 30717707, PMID 30763338, PMID 30963212, PMID 30998813, PMID 31095287, PMID 31231122, PMID 31297636, PMID 31347292, PMID 31477168, PMID 31580386, PMID 31849532, PMID 31912800, PMID 31953079, PMID 32228512, PMID 32321565, PMID 32361265, PMID 32386568, PMID 32450725, PMID 32554315, PMID 32740235, PMID 32758299, PMID 32939319, PMID 32940628, PMID 33191450, PMID 33199511, PMID 33387490, PMID 33475684, PMID 33478521
2025 (8), 2016 (7), 2017 (5), P30CA138292 (4), U10CA180820 (4), 2018 (3), 2014 (2), P30CA015083 (2), P30CA015704 (2), P30CA068485 (2), 2015 (1), 2023 (1), P01CA217797 (1), P30CA014599 (1), P30CA022453 (1)